BridgeBio

Great connecting with the neuromuscular community at #MDA2026. This year’s meeting was a great opportunity to share new data from our interim analysis of FORTIFY, our Phase 3 trial in LGMD2I/R9 and connect with clinicians, researchers, advocates, and families committed to advancing care for people living with neuromuscular conditions. Moments like these reinforce the power of partnership across advocacy, science, and policy to help move the field forward for people living with LGMD.

Encouraging to see continued momentum in DC to accelerate progress for rare disease communities and to see the patient voice represented in these important policy conversations. Proud to amplify the work of Speak Foundation, along with CureLGMD2i Foundation, Coalition to Cure Calpain 3, and LGMD2D Foundation, in support of tireless, patient-led advocacy on behalf of those living with #LGMD. Ensuring patient perspective is integrated alongside scientific expertise is critical to advancing meaningful progress. While important work remains, advocacy like this is helping drive a more informed and effective path forward.

Our goal is simple: maximize the number of meaningful medicines and the patients they reach. At our March Town Hall, Chinmay S. from our Strategic Finance team shared how BridgeBio is proving that point. Our portfolio management framework, now published in Drug Discovery Today, is built around one mission: get life-changing treatments to patients with the greatest unmet need, as fast as possible. Strong science. High probability of success. A cost structure built to keep going, program after program. As Chinmay put it, the flywheel is firmly in motion. We publish because rare disease is too vast for any one company to solve alone. If even one more company is inspired to do this work for patients, that's a success worth writing about. Read the full article: https://bit.ly/3OdxvRw #BridgeBio #TownHall #RareDisease #PortfolioManagement #PatientFirst #DrugDevelopment

This #AmyloidosisAwarenessMonth, we’re honored to share Anne Marie and Gesna’s perspectives on the progress made in the amyloidosis community in the years since they were first diagnosed. From a time when there were few answers and limited to support, to today’s growing body of research and education, their voices highlight how far the amyloidosis community has come, and why the continued fight for awareness remains paramount.

We are thrilled to share results from the ATTRibute-CM open-label extension trial in individuals with ATTR-CM through Month 54, which were featured in a late-breaking oral presentation at #ACC2026. Notably, this was the only ATTR-CM study selected for the late-breaker session, underscoring the importance of these findings for the cardiology community. The data, presented by Prem Soman, M.D., Ph.D. (University of Pittsburgh School of Medicine), are now also simultaneously published in JAMA Cardiology. In addition to the late breaking oral presentation, we shared three posters on additional OLE data and real-world survey findings. Learn more: https://bit.ly/4bxZoNh

We are thrilled to share we submitted our NDA to the FDA for BBP-418 for individuals living with LGMD2I/R9. If approved, BBP-418 will become the first therapy for LGMD2I/R9 and potentially the first approved treatment for any form of LGMD. Grateful to the participants in our trial, families, investigators, and advocates who made this milestone possible. 💚 Learn more: https://bit.ly/3O3TaLY

During #AmyloidosisAwarenessMonth, we’re raising awareness about ATTR-CM, a serious yet often misunderstood disease. Recognizing the signs can help support earlier diagnosis and informed care. To learn more about ATTR-CM, visit https://lnkd.in/e27XDjzg

Everyone loves an underdog story this time of year. We get it. We've built our entire company around them. The conditions most companies walked away from. The programs that looked too hard, too niche, too uncertain. The people told there was nothing coming for them. We always backed the long shots. That's what being impatient for patients actually looks like – not waiting for the sure thing. Racing toward the ones who need us most. Who's your underdog pick this March? 🏀 Rachel Stier, Courtney Grafe, Terralyn Bickham, Thomas T.

What’s the latest in ATTR-CM care? Hear a panel of leading experts share their insights on recent approaches to ATTR-CM diagnosis and management. They will explore ongoing gaps in care and discuss emerging clinical data in both variant and wild-type ATTR-CM for a TTR stabilizer. The program will also feature a Kansas City Chiefs Hall of Famer and advocate, who will highlight the challenges he faced throughout his diagnostic journey and his path to advocacy. #JoinTheConversation at #ACC26 on Friday, March 27, at 6:00 pm CT in Grand Ballroom D at the Hilton New Orleans Riverside in New Orleans.

We were proud to take part in the South Boston St Patrick’s Day Parade and the Chief Marshal's Banquet hosted by the South Boston Allied War Veterans Council. These meaningful community moments gave us the opportunity to help raise awareness of ATTR-CM, including the importance of education around the T60A genetic variant within the Irish American community. Thank you to everyone who welcomed us, shared in the celebration, and engaged in these important conversations.